Trial · NCT03427125
Adverse events27
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 27
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhea | Gastrointestinal disorders | Tenapanor 10 mg, 20 mg, 30 mg BID | 222 | 419 | 222 |
| other | Diarrhea | Gastrointestinal disorders | Placebo | 2 | 126 | 2 |
| other | Diarrhea | Gastrointestinal disorders | Sevelamer Carbonate | 10 | 137 | 10 |
| serious | pneumonia | Infections and infestations | Tenapanor 10 mg, 20 mg, 30 mg BID | 6 | 419 | 6 |
| serious | pneumonia | Infections and infestations | Placebo | 0 | 126 | 0 |
| serious | pneumonia | Infections and infestations | Sevelamer Carbonate | 8 | 137 | 8 |
| serious | Cellulitis | Infections and infestations | Tenapanor 10 mg, 20 mg, 30 mg BID | 6 | 419 | 6 |
| serious | Cellulitis | Infections and infestations | Placebo | 1 | 126 | 1 |
| serious | Cellulitis | Infections and infestations | Sevelamer Carbonate | 5 | 137 | 5 |
| serious | Sepsis | Infections and infestations | Tenapanor 10 mg, 20 mg, 30 mg BID | 6 | 419 | 6 |
| serious | Sepsis | Infections and infestations | Placebo | 1 | 126 | 1 |
| serious | Sepsis | Infections and infestations | Sevelamer Carbonate | 2 | 137 | 2 |
| serious | Acute Respiratory Failure | Respiratory, thoracic and mediastinal disorders | Tenapanor 10 mg, 20 mg, 30 mg BID | 8 | 419 | 8 |
| serious | Acute Respiratory Failure | Respiratory, thoracic and mediastinal disorders | Placebo | 1 | 126 | 1 |
| serious | Acute Respiratory Failure | Respiratory, thoracic and mediastinal disorders | Sevelamer Carbonate | 5 | 137 | 5 |
| serious | Fluid Overload | Metabolism and nutrition disorders | Tenapanor 10 mg, 20 mg, 30 mg BID | 7 | 419 | 7 |
| serious | Fluid Overload | Metabolism and nutrition disorders | Placebo | 1 | 126 | 1 |
| serious | Fluid Overload | Metabolism and nutrition disorders | Sevelamer Carbonate | 6 | 137 | 6 |
| serious | Hyperkalemia | Metabolism and nutrition disorders | Tenapanor 10 mg, 20 mg, 30 mg BID | 5 | 419 | 5 |
| serious | Hyperkalemia | Metabolism and nutrition disorders | Placebo | 0 | 126 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03427125/events